Market Chatter: Lundbeck Said to Explore Potential Xeris Biopharma Acquisition
MT Newswires Live
Sep 30
H Lundbeck has been working with advisers to explore acquiring Xeris Biopharma Holdings (XERS), Bloomberg reported Tuesday, citing people familiar with the matter.
There's no guarantee that Lundbeck's interest will culminate in a deal for the commercial-stage drugmaker, the report said, citing the people.
The companies didn't immediately reply to a request for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.